Author name: EuMe-adm

❌ The myth: AI is transforming medical devices. Right now. On scale. Consequently, the conference keynotes say so. The investor decks confirm it. As a result – if you are not already deploying AI, you are falling behind.  The data tells a different story.  Still Mostly in the Pilot Phase  The global market for AI-enabled medical […]

❌ The myth: A great Product sells itslef, Regulatory Strategy can come later. Many MedTech manufacturers share the same assumption: the technology works, the clinical need is clear, and regulatory paperwork is just a final admin step. This belief has delayed, derailed, and ended market entry for otherwise strong products.  Regulatory strategy is not a

Wearable Devices and Health Apps ❌ The myth: If my wearable device or health app collects data through a smartphone, smartwatch, or fitness tracker, the entire system including the consumer hardware needs CE marking as a medical device ✅ The reality: The regulatory requirements depend entirely on the intended purpose of the software, not the

A great prototype means you’re ready for market ❌ The myth: Once we have a working prototype and positive user feedback, we can quickly move through CE marking and launch ✅ The reality: A functional prototype is merely the foundation – regulatory readiness requires complete traceability throughout your entire development process. The MDR demands that

Fault Tree Analysis (FTA) excels when you need: Top-down analysis requirements: Working backwards from a known hazardous situation or adverse event to identify all possible contributing causes. FTA excels at analysing how multiple component failures or conditions could combine to create a specific undesired event. Complex system interactions: For devices where multiple subsystems must fail

Continuing our series debunking common misconceptions in Regulatory Affairs. The myth: Many MedTech manufacturers treat gap analyses as administrative exercises. Documents created to satisfy auditors or tick a compliance box. They’re often seen as retrospective paperwork rather than proactive tools. The reality: A well-executed gap analysis is a strategic planning instrument, not documentation for its

This month, the FDA replaced its 2018 Pre-RFD guidance with significant updates that impact how manufacturers prepare and submit requests. High impact changes The vague “request a meeting” approach is gone. FDA now distinguishes between two structured meeting types: informational meetings (pre-submission, 6-week timeline) and explanatory meetings (post-assessment, 2-week timeline). Your SOPs will need updating.

Your complete market access overview: now with MDSAP and CE filters Moving beyond myths to facts: Our interactive Regulatory World Map now helps you explore exact market requirements for 20+ countries – filtered by what matters to your strategy. What’s new: MDSAP status filtering: Distinguish between Member, Official Observer, and Affiliate countries CE acknowledgement filter:

Global market access is complicated enough without the added confusion of persistent myths. From misunderstood MDSAP requirements to overestimated CE marking reach, these assumptions can derail your expansion timeline and budget. Let’s set the record straight.   ❌The myth: CE mark = instant market access across all European countries ✅ The reality: Whilst the CE

Understanding the critical difference between AI assistance and Regulatory Intelligence   The question we have heard a lot since the webinar As regulatory consultants and Authorised Representative, we’re increasingly asked: “Why can’t we just use ChatGPT or other general AI tools for our regulatory questions? They’re free and seem to know about regulations.” It’s a